Anesthetic gases (isoflurane, sevoflurane, desflurane, halothane, and nitrous oxide, among others), also known as inhaled anesthetics, are administered as a primary therapy for preoperative sedation and adjunctive anesthesia maintenance to intravenous (IV) anesthetic agents (such as midazolam and propofol) in the perioperative setting.  

Market Dynamics

Increase in prevalence of chronic diseases, increase in geriatric (aging) population, rise in demand for anesthesia gases, increase in use of anesthesia during surgeries, and rise in number of surgical procedures around the world are major factors expected to propel growth of the global anesthesia gases market during the forecast period.

For instance, in February 2022, Sedana Medical announced the launch of Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane), delivered via medical device Sedaconda ACD (Anaesthetic Conserving Device), is the only approved inhaled sedation therapy for use during intensive care. Sedaconda received European DCP approval in July 2021.

Key features of the study

• This report provides in-depth analysis of the global anesthesia gases market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026–2023), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global anesthesia gases market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Baxter, AbbVie Inc., Piramal Enterprises Ltd., Fresenius SE & Co. KgaA, Drägerwerk AG & Co. KgaA, GE Healthcare, and Mindray Medical International Limited, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global anesthesia gases market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anesthesia gases market.

 Market Segmentation

• By Product Type (Revenue, USD Mn, 2021-2033)
  • Anesthesia Gases
  • Vaporizer Devices
• By Anesthesia Gases (Revenue, USD Mn, 2021-2033)
  • Desflurane
  • Sevoflurane
  • Isoflurane
  • Nitrous Oxide
  • Other Anesthesia Gases
• By End User (Revenue, USD Mn, 2021-2033)
  • Hospital
  • Ambulatory Surgical Centers
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Competitive Landscape
  • Baxter
  • AbbVie Inc.
  • Piramal Enterprises Ltd.
  • Fresenius SE & Co. KgaA
  • Drägerwerk AG & Co. KgaA
  • GE Healthcare
  • Mindray Medical International Limited